Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07200596
PHASE1

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.

Official title: The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Subcutaneous Injection of SHR-3045 in Healthy Subjects-A Randomized, Double-Blind, Dose-Escalating, Placebo-Controlled Phase I Study

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

16

Start Date

2025-10-08

Completion Date

2026-03

Last Updated

2025-11-17

Healthy Volunteers

Yes

Interventions

DRUG

SHR-3045 Injection

SHR-3045 injection.

DRUG

SHR-3045 Placebo Injection

SHR-3045 placebo injection.

Locations (1)

The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)

Hefei, Anhui, China